Literature DB >> 8513112

Testing for the existence of a desirable dose combination.

H M Hung1, G Y Chi, R J Lipicky.   

Abstract

We consider the problem of studying several dose combinations of two drugs for a therapeutic endpoint in a multilevel factorial clinical trial. Two test statistics are constructed to test whether there exists at least one dose combination that is more effective than its component doses. Their distributions involve nuisance parameters quantifying the mean differences among the doses of the two component drugs. It is shown that their power functions achieve maxima as all the nuisance parameters approach infinity in absolute value. The significance levels of the two tests are derived and two alpha-level tests are proposed. Tables are given to provide the alpha-level critical values for these tests and to gain insights into their power performances.

Mesh:

Substances:

Year:  1993        PMID: 8513112

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Generalized Confidence Intervals Compatible with the Min Test for Simultaneous Comparisons of One Subpopulation to Several Other Subpopulations.

Authors:  Julia N Soulakova
Journal:  Commun Stat Theory Methods       Date:  2017-06-07       Impact factor: 0.893

Review 2.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  Expected loss functions as additional measures to assess performance of multiple testing procedures for combination drug dose finding.

Authors:  Julia N Soulakova; Allan R Sampson
Journal:  Pharm Stat       Date:  2012-03-06       Impact factor: 1.894

4.  Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.

Authors:  Jianrong Wu; Lorraine Tracey; Andrew M Davidoff
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

5.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

6.  On Identifying Minimum Efficacious Doses in Combination Drug Trials.

Authors:  Julia N Soulakova; Allan R Sampson
Journal:  Stat Biopharm Res       Date:  2009       Impact factor: 1.452

7.  Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.

Authors:  George L Bakris; Malini Iyengar; Mary Ann Lukas; Paul Ordronneau; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-07-08       Impact factor: 3.738

Review 8.  Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

Authors:  C Ventika S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

9.  Testing multiple dose combinations in clinical trials.

Authors:  Saswati Saha; Werner Brannath; Björn Bornkamp
Journal:  Stat Methods Med Res       Date:  2019-09-24       Impact factor: 3.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.